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Expression of v3- or v5-integrins and selectins is widespread
on blood cells and endothelial cells. Here we report that human
tumor cells injected s.c. into mice lacking 3- or 35-integrins or
various selectins show enhanced tumor growth compared with
growth in control mice. There was increased angiogenesis in mice
lacking 3-integrins, but no difference in structure of the vessels
was observed by histology or by staining for NG2 and smooth
muscle actin in pericytes. Bone marrow transplants suggest that
the absence of 3-integrins on bone marrow-derived host cells
contributes to the enhanced tumor growth in 3-null mice, al-
though few, if any, bone marrow-derived endothelial cells were
found in the tumor vasculature. Tumor growth also was affected
by bone marrow-derived cells in mice lacking any one or all three
selectins, implicating both leukocyte and endothelial selectins in
tumor suppression. Reduced infiltration of macrophages was ob-
served in tumors grown in mice lacking either 3-integrins or
selectins. These results implicate cells of the innate immune sys-
tem, macrophages or perhaps natural killer cells, in each case
dependent on integrins and selectins, in tumor suppression.
tumors  bone marrow transplants  cell adhesion  innate immunity
We have previously investigated the growth and metastasisof transplanted tumors in mice lacking specific cell-
adhesion receptors, namely integrins (1–3) or selectins (4–6).
In mice lacking v-integrins (v3 and v5), tumors grow
larger; this growth is accompanied by enhanced tumor angio-
genesis (2). However, it is unclear whether other factors, such as
altered vessel morphology, pericyte recruitment, or altered
immune responses in the integrin-deficient mice, may contribute
to the enhanced tumor growth.
In the case of selectins, we have shown that experimental
metastases to the lungs are reduced in mice lacking P- andor
L-selectins (4–6). This reduction is believed to result from the
tumor cells’ expression of ligands for selectins such that selectins
on host platelets, leukocytes, or endothelial cells can bind these
ligands and promote metastatic arrest in the lungs after tail vein
injection (7–10). Examination of this hypothesis using a more
complete model of metastasis, such as metastasis from a s.c. site,
would be desirable.
Given these two prior lines of investigation and the questions
they raised, we have investigated further the s.c. growth of
xenotransplanted tumors in mice lacking various combinations
of integrins or selectins. We report here results indicating that
both 3-integrins and selectins contribute to host responses
suppressing tumor growth. In each case, bone marrow (BM)-
derived host cells, dependent on integrins or selectins, seem to
inhibit tumor growth, and in the absence of these adhesion
receptors tumors grow significantly larger.
Materials and Methods
Mice. All mice were generated in our own laboratory. 3-Integrin-
null mice (2, 11–12) were intercrossed with mice lacking the Rag2
gene (13) and with mice lacking 5-integrin (14) to generate
mice deficient in Rag2, in Rag2 and 3-integrin, or in Rag2, 3-,
and 5-integrin genes. Mice lacking all combinations of the three
selectin genes (P-, L-, and E-selectins; ref. 15) were crossed with
the Rag2-null mice to generate mice deficient in Rag2 and various
combinations of selectins. All mice used in the experiments
described here were, therefore, Rag2-null on a mixed C57BL
6  129S4 background and lacked B, T, and NKT cells. Because
of the complexities of the breeding, experimental mice having or
lacking individual adhesion genes were cousins, not siblings.
However, the effects seen were consistent among diverse exper-
iments and highly significant. Mice were maintained under
severe combined immunodeficient conditions in the Massachu-
setts Institute of Technology animal facility. All mice were viable
and fertile and generally remained healthy for the duration of the
experiments, despite occasional hemorrhage in 3-integrin-
deficient mice (11) and late-onset dermatitis in mice lacking both
endothelial selectins P and E (15, 16). In an earlier study of
metastasis, tumor growth was reduced in P-selectin-deficient
mice (4), but those mice were not kept in specific pathogen-free
conditions and showed opportunistic infections and significant
morbidity that apparently affected tumor growth.
Antibodies. Monoclonal antibodies used for immunohistochem-
istry were rat anti-platelet endothelial cell-adhesion molecule
(PECAM)-1CD31, rat anti-Pan-NK, biotinylated hamster anti-
3-integrin (all from PharMingen), mouse anti-smooth muscle 
actin (Sigma), rat anti-F480 (Serotec), and rabbit anti-NG2
polyclonal antiserum (Chemicon); all were used at a 1:100
dilution. Secondary antibodies for immunofluorescence were
Alexa Fluor-conjugated goat anti-rabbit IgG, goat anti-mouse
IgG, or goat anti-rat IgG (all from Molecular Probes). Biotin-
conjugated goat anti-rat Ig antibody used for chromogenic
analysis was from PharMingen. Fluorescence-activated cell
sorter analyses used FITC-conjugated rat monoclonal antibodies
anti-Pan-NK or anti-F480.
Immunohistochemistry and Histology. Five-micrometer frozen sec-
tions of tumors were used for immunohistochemistry. Chromo-
genic visualization followed the VECTASTAIN ABC kit pro-
tocol (Vector Laboratories). For immunofluorescence, the
conjugated secondary antibodies were used at a 1:400 dilution.
Histology was performed on 5-m paraffin-embedded or 1- to
2-m plastic-embedded tumor sections counterstained with
hematoxylineosin or with methyl green, respectively. All images
were visualized with a Zeiss Axiophot photoscope. Images were
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processed with NIH SCION IMAGE and ADOBE PHOTOSHOP (Adobe
Systems, Mountain View, CA).
Flow Cytometry. FITC-conjugated rat monoclonal antibodies
(anti-mouse Pan-NK or anti-F480) were used to stain natural
killer (NK) cells or monocytesmacrophages present in the
blood of mice. Blood samples were incubated with a 1:100
dilution of antibody for 1 h at room temperature, treated with
red cell lysis buffer (17), washed twice with PBS, resuspended in
PBS, and analyzed in a FACScan with CELLQUEST software
(Becton Dickinson).
Mouse Tumor Transplants. Eight- to 12-week-old mice were in-
jected s.c. with either 2  106 LS 180 human colon cancer cells
(ATCC no. CL-187) or 2  106 A375 SM human melanoma cells
(18). Tumors were harvested, weighed, and processed from
3 days to 5 weeks later. Every experiment was repeated at least
3 times.
Mouse BM Transplants. Eight-week-old mice (recipients) were
lethally irradiated with 1,000 rads (a dose of 600 rads followed
4 h later by a dose of 400 rads; 1 rad  0.01 Gy) and reconstituted
with an intraorbital injection of 2  106 BM cells from donors
of the desired genetic makeup. These mice were kept in sterile
conditions and fed antibiotics for 10 days. Five weeks after the
BM transplant, mice were injected s.c. with human tumor cells
and analyzed as described above.
Statistical Analysis. Data were analyzed by using a program
available at www.physics.csbsju.edustats. Tumor sizes are rep-
resented by box-and-whisker plots (Figs. 1, 3, 5, and 6) wherein
each box represents an interquartile range (IQR; the central 50%
of the data points), the horizontal line in each box represents the
median, and vertical bars represent a spread of 1.5  IQR. Dots
represent outliers, which were included in calculations of signif-
icance; n indicates the number of samples, and p indicates the
probability of identity of the distributions. In Fig. 5a, data from
several experiments were combined and expressed as percent-
ages of the mean WT value, and the box-and-whisker plots were
generated by using EXCEL (Microsoft) (19).
Results
Tumor Growth Is Enhanced in 3- or 35-Null Mice. Immunocom-
promised Rag2-null (control), Rag23-null, and Rag235-
null mice were injected s.c. with human tumor cells, either colon
carcinoma (LS 180) or melanoma (A375 SM). As shown in Fig.
1, tumors grew in all three lines of mice, but tumor size was
enhanced significantly in Rag23- or Rag235-integrin-
deficient mice when compared with Rag2-null mice WT for
integrins (P  0.0001) Differences in growth rates were seen as
early as 2 weeks after implantation.
Angiogenesis Is Not Blocked in the Absence of 3- or 35-Integrins.
Sections of human tumors were analyzed at different times after
the s.c. injections. No morphological differences were observed
among the vessels within the different tumors. Immunohisto-
chemical analysis with anti-PECAM-1, an endothelial cell
marker, revealed an increased blood vessel density in the absence
of 3-integrins (Fig. 2) or 35-integrins (data not shown), as
previously described for other tumors (2, 18). To analyze pos-
sible differences in the recruitment of vascular mural cells
(pericytes and smooth muscle cells), sections of tumors were
stained with antibodies against NG2 (Fig. 2) or smooth muscle
 actin (data not shown), markers for pericytes, and costained
with anti-PECAM-1 antibody to reveal the endothelial cells (Fig.
2 Left). Similar staining for NG2 or smooth muscle  actin was
observed around the vessels of tumors grown in control or in 3-
or 35-null mice. Thus, the absence of these integrins does not
block vessel development, which is in fact enhanced (17%)
compared with that in the WT.
Increased Tumor Growth in 3-Null Mice Is BM-Dependent. To de-
termine whether BM cells were responsible for the different
tumor growth in the various mouse lines, recipients (Rag2-null or
Rag23-null) were lethally irradiated and reconstituted with
BM derived from mice with different genetic backgrounds. Five
weeks after the BM transplants, these mice were injected s.c.
Fig. 1. Tumor growth is increased in 3- and 35-integrin-deficient mice.
Human A375 SM (Left) and LS 180 (Right) tumors grown s.c. in Rag2-null3/
and Rag23-null or Rag235-null mice. Box plots show tumor weights in
grams for 4-week-old tumors (Left) and 3-week-old tumors (Right). P  0.0001;
n, the number of animals in each group.
Fig. 2. Characterization of vasculature in human A375 SM and LS 180 tumors
grown in Rag2-null3/ or Rag23-null mice. PECAM-1 and NG2 double-
staining of 11-day-old LS 180 tumors from Rag2-null3/ or Rag23-null
mice. PECAM-1 (red) and NG2 (green) staining are present around the same
vessels. Similar results were obtained with smooth muscle  actin staining for
pericytes and with tumors grown in Rag235-null mice (data not shown).
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with tumor cells. As shown in Fig. 3, tumor growth was enhanced
only in mice reconstituted with BM cells derived from 3-null
mice. Tumor growth was reduced in all irradiated compared with
nonirradiated mice, independent of genetic makeup (note dif-
ferent scales). However, in all comparisons, mice with BM WT
for integrins supported significantly less tumor growth than did
mice with BM lacking 3-integrins. Therefore, BM-derived,
integrin-dependent, host cell type(s) suppress tumor growth.
To investigate whether the increased tumor growth in animals
that received BM transplants could be affected by endothelial
cell precursors contributing to the excess vessel growth, we
stained for 3-integrins. Tumors grown in 3-null animals
showed no staining for 3-integrin on the vessels, whereas
positive endothelial cell staining was observed on vessels of
tumors grown in Rag2-null3/ animals or in the same animals
transplanted with 3/ BM cells. However, when 3-null
animals were transplanted with Rag2-null3/ BM cells, no
positive staining for 3-integrins was observed on the endothe-
lial cells within the tumors (Fig. 8, which is published as
supporting information on the PNAS web site). This suggests
that all or most endothelial cells of the tumor vessels originate
from local host vessels and not from potential BM-derived
endothelial cell precursors. Thus, the effects of the transplants
apparently reflect circulating blood cells rather than recruitment
of endothelial progenitors.
Reduced 3-Null Macrophage Infiltration in Human Tumors. Because
the Rag2-null mice used in these experiments do not develop
mature B and T lymphocytes, increased tumor growth in animals
lacking 3- or 35-integrins could not be attributed to an
alteration in the lymphocyte population. However, it is possible
that other immune cells expressing 3- or 5-integrins were not
functioning properly and therefore could not block tumor
growth. We tested some cells involved in the innate immune
response, namely macrophages and NK cells. We analyzed the
recruitment of macrophages around and within the tumors by
staining the human tumor sections with an anti-F480 antibody
(macrophage antigen) at different times. As shown in Fig. 4,
macrophage infiltration can be observed in tumors grown in mice
WT for integrins 3 days after injection, and fewer macrophages
are present around and within the tumors grown in 3- or
35-null mice. Similar results were obtained at later times
(data not shown). Because of the uneven distributions of mac-
rophages, precise quantification was difficult, but microscopic
counts suggested a 6- to 10-fold reduction in the integrin-
deficient mice.
Immunohistochemistry experiments also were performed for
NK cells by using an anti-Pan-NK antibody. The numbers of NK
cells associated with the tumors were low in all animals, and we
could not see obvious differences (data not shown). To test
whether reduced recruitment was due to a reduced population
of monocytemacrophage lineage or NK cells in the blood of the
3-null animals, we performed fluorescence-activated cell sorter
analyses. No decrease in the F480-positive population or in NK
cells was observed in Rag23-null compared with Rag2-null
3/ mice (data not shown).
Tumor Growth also Is Enhanced in Selectin-Deficient Mice. Immuno-
compromised Rag2-null (control) or Rag2-nullP-, E-, L-, or
ELP-null mice were injected s.c. with the same two human tumor
cell lines. As shown in Fig. 5a, tumors grew in all lines of mice,
but tumor size was greatly enhanced in the absence of one or all
three selectins when compared with that in controls. The most
significant increase was observed in the triple-selectin-knockout
mice. Again, differences in growth rates were seen as early as 2
weeks after implantation and accelerated greatly after 3 weeks.
Interestingly, A375 SM tumors also showed enhanced growth in
Fig. 3. Analysis of s.c. tumors in mice after BM transplantation. Rag2-null
3/ or Rag23-null recipient (Recip.) mice were lethally irradiated and
reconstituted with BM derived from Rag23/ or Rag23-null mice and
were injected s.c. 5 weeks later with LS 180 human tumor cells. The box plots
represent the size of 3-week-old tumors. Reduced tumor growth can be
observed in mice that received Rag2-null3/ BM compared with mice that
received Rag23-null BM. (Right) Nonirradiated mice that did not receive a
BM transplant are shown for comparison. (Left) P  0.0026. (Center) P  0.042.
(Right) P  0.0014. n, Number of animals in each group.
Fig. 4. Macrophage infiltration in A375 SM tumors grown in Rag23/ or
Rag23-null mice. Sections of 3-day-old A375 SM tumors were stained with
an anti-macrophage antibody. A higher infiltration of macrophages (brown,
indicated by arrows) was observed in tumors grown in control mice (Upper)
compared with tumors grown in Rag23-null mice (Lower). Note also the
greater infiltration into the tumor in 3/ mice. (Scale bar, 160 m.)








triple-selectin-deficient mice (Fig. 5b), although these cells,
unlike LS 180 cells, do not express selectin ligands (5).
Increased Tumor Growth in ELP-Null Mice Is Partially BM-Dependent.
To determine whether BM-derived cells were responsible for the
increased tumor growth in the ELP-null mice, we performed BM
transplants as described above. Recipient Rag2-null or Rag2
ELP-null mice were lethally irradiated and reconstituted with
BM derived from either Rag2-null or Rag2ELP-null mice and
then challenged with tumor cells. As before, tumor growth was
reduced in all irradiated compared with nonirradiated mice (Fig.
6 Left; note the different scales). Tumor growth was enhanced
only in mice reconstituted with BM cells derived from ELP-null
mice (Fig. 6 Center and Right), suggesting the involvement of
selectin-dependent, BM-derived cells in suppressing tumor
growth. However, tumor growth in ELP-null mice that received
a WT selectin BM transplant was slightly more pronounced than
the growth in WT mice that received a WT BM transplant
(compare Fig. 6 Center and Right; P  0.041). This difference
suggests that a BM-independent but selectin-dependent event
also can affect tumor growth. Therefore, tumor growth is clearly
affected not only by selectin-dependent, BM-derived cells, but
also by selectins on BM-independent cells, probably endothelial
cells; these express P- and E-selectins and are the only cells that
express E-selectin, which clearly does have an effect (Fig. 5; see
also Discussion).
Reduced Macrophage Infiltration in ELP-Null Mice. We analyzed the
infiltration of macrophages and NK cells by staining with
anti-F480 (macrophage antigen) or anti Pan-NK antibody at
different times. As shown in Fig. 7, macrophage infiltration can
be observed around and within the tumors grown in Rag2-null
Fig. 5. Tumor growth is increased in selectin-deficient mice. (a) Human LS 180 s.c. tumors grown in Rag2-null or Rag2L-, E-, P-, or ELP-null mice. (b) Human
A375 SM s.c. tumors grown in WT or ELP-null mice. Box plots show the tumor weights as percentage of their size in selectin WT mice at 5 weeks (a) and in grams
at 4 weeks (b).
Fig. 6. Tumor growth is partially mediated by BM-derived cells in selectin-
deficient mice. Human LS 180 s.c. tumors grown in mice that received BM
transplants. (Center and Right) Control or selectin-null recipient (Recip.) mice
were lethally irradiated and reconstituted with BM derived from either con-
trol or selectin-deficient mice and were injected s.c. 5 weeks later with LS 180
human tumor cells. (Left) Control mice were not irradiated and did not receive
BM transplants. Box plots show the tumor weights in grams for 3-week-old
tumors.
Fig. 7. Macrophage infiltration in tumors grown in Rag2-null or Rag2ELP-
null mice. Sections of 3-day-old A375 SM (Upper) and 4-day-old LS 180 (Lower)
tumors were stained with an anti-macrophage antibody. A higher infiltration
of macrophages (purple) around and inside the tumor was observed in tumors
grown in control (Left) compared with selectin-deficient (Right) mice. Note
that the skeletal muscle near the tumor is stained nonspecifically. Arrows
indicate the areas occupied by macrophages. (Scale bar, 100 m.)
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mice 3 or 4 days after injection. Fewer macrophages are present
in and around tumors grown in Rag2ELP-null mice (a 4- to
5-fold reduction), and similar results were obtained at later times
(data not shown). The numbers of NK cells were low in all
sections, and we could not detect significant differences (data
not shown).
Fluorescence-activated cell sorter analyses of the circulating
F480-positive and NK cell populations showed no decreases in
single, double-, or triple-selectin-null mice versus Rag2-null
mice, in accord with previous results (15). We also checked for
recruitment of BM-derived endothelial progenitors (using stain-
ing for P-selectin). As in the case of integrin-deficient mice
discussed above, no recruitment was detected (data not shown).
In summary, these results indicate that selectin-dependent re-
cruitment of BM-derived circulating blood cells is important in
tumor suppression.
Discussion
The results described here show clearly that certain integrins and
all selectins expressed by host cells contribute to the suppression
of the growth of transplanted tumors. Because 3-integrins and
selectins are expressed by cells of the vessel wall (endothelial
cells, pericytes, and smooth muscle cells) and by many circulating
blood cells, these results could implicate numerous cell types in
tumor suppression.
Prior work has suggested that v-integrins (v3 and v5)
could act as negative regulators of angiogenesis (1, 2, 18), and,
indeed, we see enhanced vascularization of transplanted human
tumors in mice lacking these integrins. The vessels appear
normal, with normal investiture by pericytes, as described else-
where for vessels lacking all v-integrins (20). The normal
association of pericytes and smooth muscle cells with the vessels
suggests that failure to recruit these cells is not the reason for the
enhanced angiogenesis, as has been suggested (21). An increased
number of vessels could contribute to the enhanced tumor
growth in integrin-deficient mice. We failed to detect any
significant recruitment of BM-derived endothelial progenitors
(EPCs) (22–23) to the vessels in any of the mice, although we
cannot rule out a low level of recruitment or the possibility that
such EPCs might require both integrins and selectins for efficient
recruitment. BM-derived cells suppress, not enhance, tumor
growth, whereas EPC recruitment might be expected to have an
effect opposite to that which we observe. Be that as it may, our
experiments clearly implicate other non-vessel wall cells derived
from the BM in mediating the tumor-suppressive effects.
Given that all our experiments were conducted in Rag2-null
mice, there was no involvement of the adaptive immune system
(B, T, and NKT cells). However, many other hematopoietic cells
could be involved. Many of these cells express 3-integrins
andor L-selectin and selectin ligands (also P-selectin in the case
of platelets) and may use P- and E-selectins expressed by
endothelial cells as well as integrins during their trafficking and
extravasation (24–26). Although we certainly would not wish to
rule out platelets, mast cells, eosinophils, or other minor leu-
kocyte populations from consideration, obvious candidate cell
types for involvement are neutrophils, monocytesmacrophages,
and NK cells.
The numbers of circulating neutrophils in selectin-deficient
mice are elevated (15) and are not significantly altered in
3-integrin-null mice. Circulating NK cells are, if anything,
elevated in the integrin- and selectin-deficient mice. Histological
and immunohistological analyses of the established tumors
revealed few neutrophils or NK cells and no obvious differences
between mice WT for or deficient in selectins or integrins.
However, these results do not rule out a role for these cells,
perhaps at an early time during tumor growth or acting in a
‘‘hit-and-run’’ fashion without significant accumulation. Exten-
sive evidence for selectin-dependence of neutrophil traffic exists
(24, 26), and some data suggest a role for v3-integrin in the
arrest and extravasation of these cells (27). Neutrophils can
exhibit antitumor reactions (28). Recruitment of NK cells has
been investigated less completely. However, it has been reported
that they express the selectin ligands P-selectin glycoprotein
ligand 1 (PSGL-1) and sialyl Lewis X (SLeX) (29–30) and L-
selectin (31), and selectin–ligand interactions likely contribute to
their binding to the endothelium. It is well established that NK
cells can kill tumor cells (32–34). We have attempted to deplete
NK cells from our system, but the results were inconclusive. Such
experiments, using well defined genetic backgrounds and ap-
propriate reagents, will be required to investigate in more detail
the potential involvement of NK cells and the possible roles of
integrins and selectins in their targeting of tumors.
Monocytesmacrophages are known to use v3-integrin and
selectins in their arrest and extravasation at sites of inflammation
(35). The same could be true for their infiltration of tumors, and
we do detect fewer macrophages infiltrating tumors growing in
integrin- or selectin-deficient mice, although the numbers of
circulating monocytesmacrophages do not differ among the
strains of mice (15). Macrophages have been suggested to be
tumoricidal (36–39), although other reports have suggested that
they also can contribute to tumor growth (40–42); they probably
have both effects (42–46).
To dissect further the possible roles of NK cells and macro-
phages (and other hematopoietic cells) in the adhesion receptor-
dependent tumor suppression that we report here, it will be
necessary to perform lineage-specific reconstitution and abla-
tion (genetic or pharmacological). Those experiments should
shed light on the role of innate immunity against tumors and the
roles of specific adhesion receptors in mediating their effects.
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